- Home
- PRVA vs FOLD Comparison
PRVA vs FOLD Comparison
Compare PRVA & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRVA
- FOLD
- Stock Information
- Founded
- PRVA 2007
- FOLD 2002
- Country
- PRVA United States
- FOLD United States
- Employees
- PRVA N/A
- FOLD N/A
- Industry
- PRVA Retail: Computer Software & Peripheral Equipment
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- PRVA Technology
- FOLD Health Care
- Exchange
- PRVA Nasdaq
- FOLD Nasdaq
- Market Cap
- PRVA 2.7B
- FOLD 2.9B
- IPO Year
- PRVA 2021
- FOLD 2007
- Fundamental
- Price
- PRVA $20.68
- FOLD $6.12
- Analyst Decision
- PRVA Strong Buy
- FOLD Buy
- Analyst Count
- PRVA 14
- FOLD 10
- Target Price
- PRVA $28.50
- FOLD $16.22
- AVG Volume (30 Days)
- PRVA 1.1M
- FOLD 5.5M
- Earning Date
- PRVA 08-07-2025
- FOLD 08-07-2025
- Dividend Yield
- PRVA N/A
- FOLD N/A
- EPS Growth
- PRVA N/A
- FOLD N/A
- EPS
- PRVA 0.12
- FOLD N/A
- Revenue
- PRVA $1,801,244,000.00
- FOLD $543,141,000.00
- Revenue This Year
- PRVA $90.63
- FOLD $19.84
- Revenue Next Year
- PRVA $10.51
- FOLD $23.18
- P/E Ratio
- PRVA $175.90
- FOLD N/A
- Revenue Growth
- PRVA 6.79
- FOLD 28.25
- 52 Week Low
- PRVA $16.47
- FOLD $5.51
- 52 Week High
- PRVA $26.09
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- PRVA 33.55
- FOLD 51.42
- Support Level
- PRVA $21.76
- FOLD $5.66
- Resistance Level
- PRVA $23.15
- FOLD $6.45
- Average True Range (ATR)
- PRVA 0.66
- FOLD 0.21
- MACD
- PRVA -0.10
- FOLD 0.07
- Stochastic Oscillator
- PRVA 7.30
- FOLD 64.89
About PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.